Eledon shares surge 22.03% after-hours as positive T1D trial data show all six patients achieved insulin independence with tegoprubart's safety profile.

Eledon Pharmaceuticals (NASDAQ: ELDN) surged 22.03% in after-hours trading following the release of preliminary data from a trial evaluating tegoprubart, its investigational anti-CD40L antibody, in type 1 diabetes patients. The trial demonstrated that all six subjects achieved and maintained insulin independence after islet transplants, with some maintaining HbA1c levels as low as 4.7% for over 15 months. The therapy showed no serious infections, kidney toxicity, or neurological side effects commonly associated with existing immunosuppressants like tacrolimus. These results, presented at a diabetes research symposium and highlighted by the extension of the trial to 12 subjects, underscored tegoprubart’s potential to replace traditional immunosuppression regimens in islet transplantation. The positive clinical outcomes directly drove the sharp post-market rally, overshadowing a recent price target reduction by Guggenheim, which cited equity dilution but maintained a "Buy" rating.